Lead Product(s) : Idalopirdine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Denovo Biopharma In-Licenses Late-Stage Alzheimer's Disease Asset from Lundbeck
Details : Lundbeck gets options to re-acquire idalopirdine for predetermined undisclosed financial terms, with Denovo and Lundbeck sharing China rights in the event Lundbeck's options are exercised and Denovo retaining all global rights in the event Lundbeck's opt...
Brand Name : DB109
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 01, 2021
Lead Product(s) : Idalopirdine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?